Analysis and Commentary 9/18/20 Analysis and Commentary 9/18/20 Public Trust in the US FDA Read More Analysis and Commentary 5/15/20 Analysis and Commentary 5/15/20 How H.R. 6800 Might Impact the FDA Read More Advocacy at a Glance 5/15/20 Advocacy at a Glance 5/15/20 Advocacy at a Glance Read More Advocacy at a Glance 5/8/20 Advocacy at a Glance 5/8/20 Advocacy at a Glance Read More Advocacy at a Glance 5/1/20 Advocacy at a Glance 5/1/20 Advocacy at a Glance Read More Analysis and Commentary 4/17/20 Analysis and Commentary 4/17/20 The COVID-19 Pandemic and Maintenance of a Continued Safe Food Supply Read More Advocacy at a Glance 4/17/20 Advocacy at a Glance 4/17/20 Advocacy at a Glance Read More Analysis and Commentary 4/3/20 Analysis and Commentary 4/3/20 Advocating for a Responsibility-based "Ask" Read More Advocacy at a Glance 4/3/20 Advocacy at a Glance 4/3/20 Advocacy at a Glance Read More Analysis and Commentary 3/27/20 Analysis and Commentary 3/27/20 Coronavirus, Pandemic Preparedness, and Beyond Read More Advocacy at a Glance 3/19/20 Advocacy at a Glance 3/19/20 Advocacy at a Glance Read More Analysis and Commentary 3/13/20 Analysis and Commentary 3/13/20 "Cures," Coronavirus, NDD, and Other Issues for FY 21 Read More Analysis and Commentary 3/5/20 Analysis and Commentary 3/5/20 Additional funding for FDA; more Qs and As Read More Advocacy at a Glance 3/5/20 Advocacy at a Glance 3/5/20 Advocacy at a Glance Read More
Analysis and Commentary 5/15/20 Analysis and Commentary 5/15/20 How H.R. 6800 Might Impact the FDA Read More
Analysis and Commentary 4/17/20 Analysis and Commentary 4/17/20 The COVID-19 Pandemic and Maintenance of a Continued Safe Food Supply Read More
Analysis and Commentary 4/3/20 Analysis and Commentary 4/3/20 Advocating for a Responsibility-based "Ask" Read More
Analysis and Commentary 3/27/20 Analysis and Commentary 3/27/20 Coronavirus, Pandemic Preparedness, and Beyond Read More
Analysis and Commentary 3/13/20 Analysis and Commentary 3/13/20 "Cures," Coronavirus, NDD, and Other Issues for FY 21 Read More
Analysis and Commentary 3/5/20 Analysis and Commentary 3/5/20 Additional funding for FDA; more Qs and As Read More
